ENDRA Life Sciences (NDRA) Equity Average (2017 - 2026)

ENDRA Life Sciences (NDRA) has 10 years of Equity Average data on file, last reported at $2.0 million in Q1 2026.

• Equity Average for Q1 2026 came in at $2.0 million, down 6.17% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.0 million (down 6.17% YoY), and the FY2025 annual result was $2.4 million, down 41.35% from the prior year.
• Equity Average grew to $2.0 million in Q1 2026 per NDRA's latest filing, from $1.2 million in the prior quarter.
• Over five years, Equity Average peaked at $11.8 million in Q3 2022 and troughed at $822265.5 in Q3 2025.
• A 5-year average of $5.6 million and a median of $5.7 million in 2023 frame the typical range for Equity Average.
• The sharpest annual moves came in 2024 and 2025: Equity Average grew 28.63% in 2024, then slumped 89.46% in 2025.
• A 5-year view of Equity Average shows it stood at $8.7 million in 2022, then sank by 37.64% to $5.4 million in 2023, then dropped by 15.57% to $4.6 million in 2024, then plunged by 73.47% to $1.2 million in 2025, then soared by 66.44% to $2.0 million in 2026.
• Business Quant data shows NDRA's Equity Average at $2.0 million in Q1 2026, $1.2 million in Q4 2025, and $822265.5 in Q3 2025.